10x Genomics (NASDAQ:TXG) Price Target Lowered to $18.00 at Stifel Nicolaus

10x Genomics (NASDAQ:TXG) had its price target reduced by Stifel Nicolaus from $21.00 to $18.00 in a research note published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also weighed in on TXG. Leerink Partners lowered shares of 10x Genomics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $25.00 to $12.00 in a research report on Thursday. Barclays lowered their target price on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Monday. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, February 1st. Citigroup reduced their price objective on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. dropped their target price on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $20.71.

10x Genomics Trading Down 0.5 %

Shares of TXG opened at $11.94 on Thursday. 10x Genomics has a fifty-two week low of $10.80 and a fifty-two week high of $51.22. The firm has a 50-day simple moving average of $14.75 and a 200-day simple moving average of $17.43.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. Equities research analysts predict that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Institutional Trading of 10x Genomics

Large investors have recently bought and sold shares of the company. FMR LLC boosted its position in shares of 10x Genomics by 0.6% in the 4th quarter. FMR LLC now owns 13,454,434 shares of the company’s stock worth $193,206,000 after buying an additional 86,455 shares in the last quarter. ARK Investment Management LLC raised its position in 10x Genomics by 11.1% during the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock worth $171,517,000 after acquiring an additional 1,193,712 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in 10x Genomics by 3.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock worth $143,907,000 after acquiring an additional 230,145 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of 10x Genomics in the fourth quarter valued at about $26,308,000. Finally, Geode Capital Management LLC grew its position in shares of 10x Genomics by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock valued at $41,009,000 after purchasing an additional 42,777 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.